Literature DB >> 18784469

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

Bénédicte Roquebert, Laurent Blum, Gilles Collin, Florence Damond, Gilles Peytavin, Juliette Leleu, Sophie Matheron, Geneviève Chêne, Françoise Brun-Vézinet, Diane Descamps.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18784469     DOI： 10.1097/QAD.0b013e32830f4c7d

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  19 in total

Review 1.  Drug resistance in HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

3.  Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Authors:  Charlotte Charpentier; Bénédicte Roquebert; Olivier Delelis; Lucile Larrouy; Sophie Matheron; Roland Tubiana; Marina Karmochkine; Xavier Duval; Geneviève Chêne; Alexandre Storto; Gilles Collin; Antoine Bénard; Florence Damond; Jean-François Mouscadet; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

Review 4.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

5.  Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions.

Authors:  Supachai Sakkhachornphop; Supat Jiranusornkul; Kanchanok Kodchakorn; Sawitree Nangola; Thira Sirisanthana; Chatchai Tayapiwatana
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

6.  HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

Authors:  Daniela Francisci; Laura Martinelli; Liliana E Weimer; Maurizio Zazzi; Marco Floridia; Giulia Masini; Franco Baldelli
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

7.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

8.  Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

Authors:  Robert A Smith; Dana N Raugi; Nancy B Kiviat; Stephen E Hawes; James I Mullins; Papa S Sow; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

9.  Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

Authors:  Mark G Lewis; Sandro Norelli; Matt Collins; Maria Letizia Barreca; Nunzio Iraci; Barbara Chirullo; Jake Yalley-Ogunro; Jack Greenhouse; Fausto Titti; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2010-03-16       Impact factor: 4.602

Review 10.  Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

Authors:  Jamie D Croxtall; Susan J Keam
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.